以色列科学家针对共同的癌症突变开发了一种新的免疫疗法,以治疗抗药性前列腺癌。 Israeli scientists developed a new immunotherapy targeting shared cancer mutations to treat drug-resistant prostate cancer.

以色列Weizmann科学研究所的研究人员制定了治疗抗药性癌症的新战略,针对共同的突变造成抗药性,使用名为SpotNeoMet的工具,确定常见的转移性前列腺癌新抗原。 Researchers at Israel's Weizmann Institute of Science have developed a new strategy to treat drug-resistant cancers by targeting shared mutations that cause resistance, using a tool called SpotNeoMet to identify common neo-antigens in metastatic prostate cancer. 这些新抗原是癌症细胞独有的,引发了实验室和老鼠模型的免疫反应,提供了潜在的宽频免疫治疗方法。 These neo-antigens, unique to cancer cells, triggered immune responses in lab and mouse models, offering a potential broad-spectrum immunotherapy approach. 这些结果发表在2025年12月29日《癌症发现》上,可能导致对不再适应标准疗法的高级癌症进行可扩展治疗。 The findings, published in Cancer Discovery on December 29, 2025, could lead to scalable treatments for advanced cancers that no longer respond to standard therapies.